Resumo

BAGANET COBAS, Aymara et al. Use of radiosynoviorthesis with chromic phospate suspensión in hemophilic patients. Rev Cubana Ortop Traumatol [online]. 2014, vol.28, n.1, pp. 2-13. ISSN 0864-215X.

Introduction: hemophilia is defined as an X chromosome-linked congenital anomaly that mainly occurs in males whereas females just carry the disease. Objective: to evaluate the safety and the effectiveness of radiosynoviorthesis using ³²P chromic phosphate manufactured by CENTIS to treat the chronic synovitis in hemophilic patients. Methods: the patients who presented with more than three hemarthoses in a month were included in the study. After the patients' consent, they were injected 1 mCi of the radionuclide in the affected joint. The migration of the radiopharmaceutical was then monitored 10 minutes after the procedure as well as 1, 7 and 30 days following the treatment. Hematological and cytogenetic studies were also performed before and one year after the treatment. The bleeding frequency rate, pain and the consumption of anti-hemophilic factor were determined. Ten knees from 9 patients received this therapy (hemophilia A in 88.9 % and hemophilia B in 11.1 %). The average age of patients was 36.3 years, with a range of 23 to 59 years. Results: there was neither significant joint leakage nor hematological change. The chromosomal study yielded normal values. Before the radiosynoviothesis with ³²P, the patients exhibited a bleeding frequency rate of 10.3 times a month (range 7-13, SD ± 2.2), but this rate lowered to 0.8 (P< 0.0001) within the 12 months after the procedure (range 0-4, SD ± 1.23). Conclusions: radiosynoviorthesis with chromic phosphate is a safe effective procedure to treat chronic synovitis in the hemophilic patient.

Palavras-chave : radiosynoviorthesis; hemophilia; chromic phosphate.

        · resumo em Espanhol | Francês     · texto em Espanhol     · Espanhol ( pdf )